334 Aidisheng Road
Zhangjiang High-tech Park
32 articles about Viva Biotech
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Viva Biotech Holdings Group announced that during the period ended June 30, 2023, the revenue of the Group during the Reporting Period increased by approximately 3.0% from RMB1,108.7 million for the corresponding period of last year to RMB1,142.2 million; and the gross profit increased by approximately 17.7% from RMB345.0 million for the corresponding period of last year to RMB406.0 million.
In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies.
On June 11, 2023, Viva Biotech Holdings Group announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Future Leadership Summit, 2023 China - Yangzhou Biopharmaceutical Forum, 2023 Dalian Biopharmaceutical Industry Conference and International Gene Festival, etc.
Recently, 6 of Viva's portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
Focus-X Therapeutics, a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd.
Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi
As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world.
Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2022 (the "Reporting Period"), the revenue of the Group increased to RMB1,108.7 million from RMB1,026.5 million for the corresponding period last year, representing a YoY increase of approximately 8.0%.
Viva Biotech 2022 Partnership Summit was successfully held.
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Viva Biotech Holdings announced that during the year ended December 31, 2021, the revenue of the Group increased significantly to RMB2,104.1 million from RMB697.0 million for the corresponding period last year, representing a YoY increase of approximately 201.9%, gross profit increased substantially from RMB304.9 million for the corresponding period last year to RMB651.0 million, representing a YoY increase of 113.5%.
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
Viva Biotech Holdings and XLement, invested and incubated by Viva BioInnovator, are committed to the production of oral COVID-19 drugs and virus test, contributing to the fight against the COVID-19 pandemic.
Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the "Reporting Period"), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
Viva Biotech declared that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.
Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology
Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou.
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS B usiness I ncreased S ignificantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion
Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders
March 2 nd -6 th , 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leaders.
Viva Biotech's Online Investor Day was successfully hosted on December 8, 2020. The management team conducted an online dialogue with nearly 400 investors, focusing on the company's strategy, personnel plans, technology platforms, integration strategic plans, investment incubation, and more.
Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities
Viva Biotech Co., Ltd. entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interest in SYNthesis med chem Limited, at the consideration of approximately US$ 80 million.
Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program
Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones. The pursuit of a convenient, oral PCSK9-based therapy has bee